 the results of pooled analysis
from the Carotid Stenting Trialists Collaboration. This
included the EVA-3S trial, the SPACE trial, and the ICSS.
In this study of 1546 CAS patients, neither lifetime stenting experience excluding the carotid nor lifetime CAS
experience impacted 30-day risk of death or stroke. However, annual in-trial CAS operator volume signiÔ¨Åcantly
impacted outcomes such that low-volume providers
(mean